Department of Cardiothoracic Surgery, King's College Hospital, London, United Kingdom.
EuroIntervention. 2017 Jun 20;13(3):280-283. doi: 10.4244/EIJ-D-16-00970.
We report the first-in-man implantation of the Mitra-Spacer. The device was implanted transapically. FMR was reduced to moderate. At two months, while in NYHA Class II, LVEF had improved, but FMR increased and 2 mL was added, reducing FMR to mild. Despite anticoagulation, thrombi developed around the device and the valve was replaced at eight months. The Mitra-Spacer successfully bridged this patient to surgery after LVEF had recovered.
我们报告首例经心尖植入 Mitra-Spacer 的临床应用。该装置采用经心尖途径植入。二尖瓣反流（FMR）减少至中度。术后 2 个月，患者心功能 NYHA 分级 II 级，左心室射血分数（LVEF）改善，但 FMR 增加，二尖瓣环成形环（2 枚）植入，FMR 减少至轻度。尽管抗凝治疗，但器械周围仍形成血栓，在 8 个月时更换瓣膜。Mitra-Spacer 在左心室射血分数恢复后成功地为该患者过渡到手术治疗。
